Enhance your patent search with AI. Try the FREE AI-powered tool

Diabetes, cancer still top areas for innovation: U.S. pharmaceuticals patent landscape report

Our analysis of the U.S. pharmaceutical patent landscape in 2023 reveals that diseases like diabetes, respiratory conditions, and cancer remain at the forefront innovation. These diseases align closely with the leading causes of death reported by The US Centers for Disease Control and Prevention in 2021. Our report on the U.S. Pharmaceuticals Patent Landscape resulted […]

2023 U.S. Granted Patents: Samsung maintains patent leadership

2023 U.S. Granted Patents: Samsung maintains patent leadership

According to our data, the USPTO granted a total of 345,344 patents in 2023 (FY 2023, spanning from October 1, 2022, to September 30, 2023). In this 2023 Patent Roundup series, we looked at patents granted by the USPTO in 2023 and analyzed the patenting trends of the top 10 assignees. Analyzing patent grants provides […]

Patent Snapshot: Neuralink

neuralink patents brain computer interface

In May 2023, Neuralink, the neurotech startup co-founded by Elon Musk, achieved a milestone by securing FDA approval for human trials of its brain implant, Link.

Subscribe to our newsletter

  • Questions? Check our privacy policy.
  • This field is for validation purposes and should be left unchanged.

Patent and IP updates straight to your inbox

Sign up now to receive monthly patent news, analysis and free insight reports.

We don’t spam, we promise.


1. Parola Analytics and Avontis are distinct entities and operate independently. Any references to Avontis or its services do not constitute a legal partnership. 

2. Parola Analytics does not provide legal services. Our services are limited to research and technical analysis. Any information provided by Parola Analytics should not be construed as legal advice.